Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keta-Care: Intranasal Ketamine for Depression in Palliative Cancer
NCT06665568Phase 1Not yet recruiting
- Sponsor
- University of Zurich
- Start
- Apr 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ketamine in major depressive disorder (MDD) and anxiety disorder, sponsored by University of Zurich. Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 8 weeks. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on NCT06665568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06665568.